| Literature DB >> 35277150 |
C Côté1,2, M Bérubé3,4, L Moore1,5, F Lauzier1,6, L Tremblay7, E Belzile8, M-O Martel9, G Pagé10,11, Y Beaulieu8, A M Pinard6, K Perreault12,13, C Sirois14, S Grzelak1,2, A F Turgeon1,6.
Abstract
BACKGROUND: Long-term opioid use, which may have significant individual and societal impacts, has been documented in up to 20% of patients after trauma or orthopaedic surgery. The objectives of this scoping review were to systematically map the research on strategies aiming to prevent chronic opioid use in these populations and to identify knowledge gaps in this area.Entities:
Keywords: Opioids; Orthopaedic surgery; Preventive strategies; Trauma
Mesh:
Substances:
Year: 2022 PMID: 35277150 PMCID: PMC8917706 DOI: 10.1186/s12891-022-05044-y
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Flow diagram on evidence screened, assessed for eligibility, and included in the review
Study characteristics, description of strategies and outcomes
| First author, year, country | Design | Sample size | Age in years mean | Female% | Type of trauma or surgical procedure | Intervention (strategies) | Comparator | Outcomes | Results |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| | |||||||||
Chambers 2021 USA [ | Prospective cohort | 86 | 37 | 40% | Outpatient orthopaedic trauma surgery | Implementation of the Orthopaedic Trauma Association (OTA) pain management guidelines for acute musculoskeletal injuries | Before guidelines implementation | Cumulative MED |
I; 210.00; C: 225.00, 95% CI -85.00 - 20.00, |
| Proportion of patients who received opioid refill(s) | I: 2.00%; C: 2.00%, 95% CI -9.00 - 8.00, | ||||||||
| Proportion of patients using opioids (adherent vs non-adherent to guidelines for discharge prescription) |
Adherent: 17.00%; Non-adherent: 13.00% 95% CI − 22.00 - 13.00
| ||||||||
Chen 2020 USA [ | Prospective cohort | 2,940 | 57 | 53% | Orthopaedic surgery including for traumatic fractures | A patient-specific protocol using an opioid taper calculator to standardize opioid prescribing at discharge after inpatient orthopaedic surgery | Before protocol implementation | MED |
I:
|
Refills mean |
I: 1.71; C: 1.58, | ||||||||
Reid 2020 USA [ | Retrospective cohort | 753 | 57 | 56% | Orthopaedic trauma | State of Rhode Island legislation on strict opioid prescription limits. These limits prohibited providers from prescribing more than 30 MED per day, 150 total MED, or 20 total doses initially following a surgical procedure. | Idem as Reid 2019 | Cumulative MED |
I: Opioid-tolerant: I: Opioid-naïve: I:
I: 265.10; C: 256.70, Opioid-tolerant: I: 923.80; C: 1,691.10, Opioid-naïve: I: 241.10; C: 206.90, |
Wyles 2020 USA [ | Retrospective | 4,523 | 63 | 51% | Orthopaedic and spine surgery including for traumatic fractures | Implementation of procedure-specific guidelines for discharge opioid prescriptions | Before guidelines implementation | MED |
I:
|
| Proportion of patients who received opioid refill(s) |
I: 24.00%; C: 25.00%
| ||||||||
Choo 2019 USA [ | Retrospective cohort | 830 | 63 | 48% | Orthopaedic surgery including for traumatic fractures | A quality improvement project using report sent to health professionals every two months, which showed median discharge MED per patient and reinforcement on multimodal pain management strategies | Before quality improvement project implementation | MED |
I:
|
| Proportion of patients who received opioid refill(s) |
I: 24.00%; C: 25.70%,
I: 14.90%; C: 14.20%,
I: 7.80%; C: 6.50%, | ||||||||
Reid 2019 USA [ | Retrospective cohort | 1,776 | 55 | 55% | Orthopaedic surgery including for traumatic fractures | Idem as Reid 2019 | Before legislation implementation | Cumulative MED |
I: Opioid-Tolerant: I:
Opioid-Naïve: I:
I: Opioid-Tolerant: I: 804.60; C: 892.60, Opioid-Naïve: I: |
| Proportion of patients using opioids |
I: | ||||||||
Young 2019 USA [ | Retrospective cohort | 218 | 75 | 72% | Minor non-surgical trauma | After Ohio's opioid prescription limit (opioids for 7 days and a total of 210 MEDs) | Before opioid prescription limit | Cumulative MED |
I: |
Earp 2018 USA [ | Retrospective cohort | 518 | 54 | 61% | Hand and upper-extremity surgeries including for traumatic fractures | Postoperative opioid-limit prescribing protocol | Before protocol implementation | MED |
Tierb 1: I: Tier 2: I: Tier 3: I: Tier 4: I: Tier 5: I: MED decreased by a minimum of 97.80% and a maximum of 176.00% ( |
| Proportion of patients who received opioid refill | 1 refill: I: 2 refills: I: | ||||||||
| | |||||||||
Cunningham 2021 USA [ | Retrospective cohort | 230 | 64 | 65% | Distal femur fracture surgery | Regional anesthesia | Without regional anesthesia | Cumulative MED |
I: 95.10; C: Incident rate ratio :
I: 112.10; C: Incident rate ratio :
I : OR
|
Cunningham 2021 USA [ | Retrospective | 230 | 41 | 35% | Pelvis and acetabulum fracture surgery | Regional anesthesia | Without regional anesthesia | Cumulative MED |
I: 177.20; C:145.20 Incident rate ratio : 1.22, 95% CI 0.99-1.51,
I: 207.90; C: Incident rate ratio 95% CI 1.06-1.65, |
| Opioid fill | Between 6 weeks to 3 months: I : OR | ||||||||
Bhashyam 2018 USA [ | Prospective cohort | 500 | 50 | 50% | Orthopaedic trauma | Recreational use or self-medication with marijuana I1: Prior user I2: Use during recovery | Never use marijuana | Total prescribed MED |
Marijuana used during recovery compared to never users (mean difference = |
| Duration of opioid use (days) | Marijuana used during recovery compared to never users (mean difference = | ||||||||
| Proportion of patients using opioids (%) |
I1: 25.90%; I2: 21.70%; C: 17.60%, no significance test | ||||||||
Radi 2017 USA [ | Retrospective cohort | 216 | NS | 37% | Orthopaedic trauma | Peri-operative regional nerve block (single shot) | No block | Proportion of patients using opioids |
I: 44.20%; C: 34.80%,
I: 7.70%; C: 14.60%, |
Yazdani 2016 Iran [ | Randomized controlled trial | 60 | 32 | 17% | Trauma: ORIF of a recent mandibular unilateral body fracture | A 100 mg dose of Amantadine one hour before surgery | Placebo capsule | Cumulative MED |
I: 121.70; C: 106.00, |
Gray 2011 Australia [ | Randomized controlled trial | 90 | 36 | 17% | Burn injury | Pregabalin (75 mg to 300 mg titration according to pain level) twice daily for 28 days and weaned and ceased over the next 6 days. | Placebo capsules | Morphine Parenteral Equivalent/ day |
I: 14.92; C: 14.92, |
| | |||||||||
Bérubé 2021 Canada [ | Randomized controlled trial | 49 | 41 | 25% | Traumatic injury requiring hospital- ization. Patients receiving > 2 doses/ day of opioid at discharge and with at least one risk factor for chronic opioid use | TOPP-Trauma programme + UC. This educational program (2 x 10 min session prior discharge and max 6 x 15 min opioid tapering counselling session every 2 weeks after discharge) focused on multimodal pain management strategies and guidance about opioid tapering | UC + an educational pamphlet received before discharge | Reported MED/day |
I: 1.20; C: 12.20, 95% CI –22.00-0.10
I: 0.40; C: 4.10, 95% CI – 8.30-0.70 |
| Total MED delivered |
I: 618.19; C: 1,009.00, 95% CI –1,324.00-542.10
I: 679.00; C: 1,443.40, 95% CI – 1,781.60-248.60 | ||||||||
| Proportion of patients using opioids (%) |
I: 17.00%; C: 29.00%,
3 months: I: 12.00%; C: 16.00%,
| ||||||||
Syed 2018 USA [ | Randomized controlled trial | 134 | 59 | 32% | Arthroscopic rotator cuff repair | Formal education detailing recommended postoperative opioid usage, side effects, dependence, and addiction | Preoperative education regarding surgery | Cumulative MED |
I:
I: |
| Opioids discontinua-tion |
OR: | ||||||||
Stanek 2015 USA [ | Retrospective cohort | NS | NS | NS | Hand surgery including for traumatic fractures | Implementation of an educational assist device to serve as a memory prompt of narcotic guidelines | Before implementation of the educational assist device | Reduction in opioid prescription (%) |
Repair of a metacarpal fracture: |
Holman 2014 USA [ | Retrospective cohort | 613 | 43 | 38% | Orthopaedic trauma | A standardized discussion with patients aiming to inform them that they would receive opioids for a maximum of 6 weeks postoperatively | No standardized discussion but limited postoperative opioids prescriptions to 12 weeks | Proportion of patients using opioids |
I:
I: 20.00%; C: 20.00%, |
| | |||||||||
Singer 2021 USA [ | Retrospective cohort | 620 | 49 | 32% | Hospitalized trauma patients | Multimodal analgesia protocol and corresponding electronic medical record order set (including opioids, NSAID and gabapentin who were adjusted for age and medical condition) | Before implementation of multimodal protocol. | Cumulative outpatient MED |
I:
|
Proportion of patients using opioids chronically (opioid prescription at 6 mo) | I: 3.20%; C:3.10%,
| ||||||||
| | |||||||||
Crawford 2019 USA [ | Randomized controlled trial | 233 | 45 | 39% | Lower extremity surgery including for traumatic injuries (military population) | Standard care and modified battlefield acupuncture with semi-permanent needles | C1: standard care + small adhesive bandages on the ear C2 | Cumulative MED |
I: 257.00; C1: 358.00; C2: 266.00, |
| | |||||||||
|
| |||||||||
| | |||||||||
Chalmers 2021 USA [ | Retrospective cohort | 19428 | 63 | 53% | THA or TKA | Modification of routine discharge MED (C = 750 MED, I1 = 520 MED, I2 = 320 MED) | Before routine discharge reduction (C) | Cumulative MED (mean) |
Total population: I1: |
| Postoperative refill in MED (mean) | Total population: I1: | ||||||||
| Proportion of patients who received opioid refill(s) | Total population: I1:
| ||||||||
Cunningham 2021 USA [ | Retrospective cohort | 4,592 | 61 | 57% | ACDF, ACLR, CTR, RCR, TAA, THA, TKA, trapeziec-tomy with suspension-plasty | North Carolina legislation. The STOP Act requires to review a patient’s 12-month history before issuing an initial prescription for an opioid and instituting a 5-day limit on initial prescriptions for acute pain and a 7-day limit on postoperative prescriptions + institutional educational materials for practitioners and patients about responsible opioid prescribing, opioid use, and North Carolina law (I1: immediately after implementation; I2: 1 year after implementation) | Before implementation of the STOP Act legislation and departmental policies (C) | Total MED prescribed |
I1:
|
| Proportion of patients who received more than one prescription | I1: C: 37.20%, | ||||||||
Raji 2021 USA [ | Retrospective case-control | 334 | 69 | 65% | Different types of shoulder arthroplasty | After Ohio legislation which limit opioid prescriptions to no more than 7 days at a time for adults, with a maximum allotted dose per day of 30 morphine milligram equivalents | Before implementation of Ohio legislation | Total MED |
Total: I:
Opioid tolerant: I: 740.00; C: 825.00,
Oioid naïve: I:
Total: I: 0.00; C: 0.00,
Opioid tolerant: I: 360.00; C: 300.00,
Oioid naïve: I: 0.00; C: 0.00,
Total: I: 0.00; C: 0.00,
Opioid tolerant: I: 405.00; C: 300.00,
Oioid naïve: I: 0.00; C: 0.00,
Total: I:
Opioid tolerant: I: 1,680.00; C: 1,455.00,
Oioid naïve: I:
|
Sabesan 2021 USA [ | Retrospective cohort | 143 | 73 | 56% | Primary reverse shoulder arthroplasty | After Florida House bill 21 law (restriction of 3 to 7-days supply of opiates for acute pain) | Before House Bill 21 law. | Cumulative MED |
I:
|
| Proportion of patients who received opioid refill(s) | I:
| ||||||||
Proportion of patients using opioids chronically (for 3 or more months of continuous usage) | I:
| ||||||||
Eley 2020 USA [ | Retrospective cohort | 246 | 59 | 38% | Spine surgery | Implementation of an opioid prescription-limit protocol | Before protocol implementation | MED |
I:
|
| Proportion of patients who received opioid refill |
I: 17.10%; C: 16.50%, | ||||||||
| Proportion of patients transitioning to chronic opioid use | I: 2.40%; C: 4.60%, | ||||||||
Joo 2020 USA [ | Retrospective cohort | 83 | 67 | 1% | Spine surgery | An individualized discharge opioid prescribing and tapering protocol | Before protocol implementation | Cumulative MED (median) Proportion of patients who received opioid refill(s) |
I: I: 36.80%; C: 40.00%, |
Tamboli 2020 USA [ | Retrospective cohort | 49 | 68 | 8% | THA | Multidisciplinary patient-specific opioid prescribing and tapering protocol | Before protocol implementation | Cumulative MED (median) |
I: MD: 721, 95% CI 127.00-1,316.00, |
| Proportion of patients who received opioid refill | I: 54.00%; C: 48.00%, > 1 refill: I: 54.00%; C: 67.00%, | ||||||||
Whale 2020 USA [ | Retrospective cohort | 1,994 | 68 | 62% | THA or TKA | After Ohio Opioid Prescribing Guidelines | Before implementation of prescribing guidelines | Cumulative MED | Total (acute and chronic follow-ups): TKA cohort: All: I: THA cohort: All: I:
TKA cohort: I: THA cohort: I: 178.60; C: 232.10,
TKA cohort: All: I: 148.80; C: 178.10, THA cohort: All: I: 69.00; C: 121.80,
|
| Proportion of patients who received opioid refill(s) |
TKA: I: 47.20%; C: 41.50%, THA: I: 25.70%; C:
TKA: I: 12.00%; C: 12.70%, THA: I: 9.50%; C: 10.00%, | ||||||||
Chen 2019 USA [ | Retrospective cohort | 60,056 | 65 | 7% | TKA (veteran population) | Opioid safety initiative that combined education, guideline dissemination with audit and feedback using dashboards | Before opioid safety initiative implementation | Proportion of patients using opioids chronically (for greater than 3 months in a 6-month period) |
Post-operative chronic user: I:
|
Holte 2019 USA [ | Retrospective cohort | 399 | 61 | 52% | TKA and THA | Implementation of strict postoperative opioid prescription guidelines and mandatory preoperative patient education session led by nursing staff regarding postoperative pain management with an emphasis on opioid use | Before implementation of guidelines | MED |
I:
|
| Total postoperative refill in MED |
I: | ||||||||
| Number of refills (mean) | I: | ||||||||
| Number of call-ins pertaining to pain management (mean) | I: | ||||||||
Reid 2019 USA [ | Retrospective cohort | 1,125 | 67 | 62% | THA or TKA | State of Rhode Island legislation on strict opioid prescription limits. These limits prohibited providers from prescribing more than 30 MED per day, 150 total MED, or 20 total doses initially following a surgical procedure. | Before legislation implementation | Cumulative MED |
I: Opioid-Tolerant: I: 1,288.00; C: 1,398.00, Opioid-Naïve: I:
I: 270.00; C: 279.00, Opioid-Tolerant: I: 1,119.00; C: 898.00, Opioid-Naïve: I: 100.00; C: 139.00, |
| Number of refills |
I: 2.20; C: Opioid-Tolerant: I: Opioid-Naïve: I: 2.10; C: | ||||||||
Reid 2019 USA [ | Retrospective cohort | 211 | 52 | 54% | Spine Surgery | Idem | Idem | Number of prescriptions (n) |
I: 1.70; C:1.60, |
| Cumulative MED |
I: Opioid-Tolerant: I: Opioid-Naïve: I:
I: 129.50; C: 181.00, Opioid-Tolerant: I: 407.90; C: 546.20, Opioid-Naïve: I: 150.30; C: 207.00,
I: 91.90; C: 153.60, Opioid-Tolerant: I: 226.70; C: 272.20, Opioid-Naïve: I: 87.90; C: 126.10,
I: 131.20; C: 136.80, Opioid-Tolerant: I: 181.20; C: 274.00, Opioid-Naïve: I: 53.70; C: 81.00, | ||||||||
Vaz 2019 USA [ | Prospective cohort | 196 | 68 | 58% | THA or TKA | Standardized opioid prescription protocol: maximum of 30 pills (370 MED) for THA and 40 pills (490 MED) for TKA | Postoperative analgesic prescription at provider’s discretion | Cumulative MED |
TKA cohort: I: THA cohort: I: |
| Proportion of patients who received opioid refill(s) | TKA cohort: I: 50.00%; C: THA Cohort: I: 16.00%; C: 8.00%, | ||||||||
Wyles 2019 USA [ | Retrospective cohort | 2573 | 67 | 53% | TKA or THA | Clinicians were recommended to prescribe a maximum MED for an opioid prescription based on the procedure level: Level 1 = 100 MED, Level 2 = 200 MED, Level 3 = 300 MED, and Level 4= 400 MED | Prescriptions without guidelines | Cumulative MED (median) |
TKA cohort: I: THA cohort: I: |
| Proportion of patients who received opioid refill(s) | TKA cohort: I: 35.00%; C: 35.00%, THA cohort: I: 17.00%; C: 16.00%, | ||||||||
| | |||||||||
| Burns 2021 USA [ | Randomized controlled trial | 157 | 61 | 52% | Scheduled shoulder arthroplasty (group 1) or ARCR (group 2) | Celecoxib 200 mg twice daily for 3 weeks | Placebo medication | Difference in MED between I and C group (ß) |
Total population: – Group 1 – Group 2: –94.50 |
Zhuang 2020 China [ | Randomized controlled trial | 246 | 68 | 80% | TKA | Supplied sequential treatment with intravenous parecoxib 40 mg (every 12 hours) for the first 3 days after surgery, followed by oral celecoxib 200 mg (every 12 hours) for up to 6 weeks | Placebo medication | Cumulative MED (median) |
I: Median difference:
I: Median difference: |
Starr 2019 USA [ | Randomized controlled trial | 11,614 | 66 | 6% | TKA (veteran population) | β-blocker within 90 days prior to surgery, β-blocker as an inpatient on postoperative day 0 or 1, and refill prescription for a β-blocker within 90 days after surgery | No β-blocker | Cumulative MED |
I: |
| Proportion of patients using opioids |
OR
OR 1.00, 95% CI 0.87-1.15,
OR 1.04, 95% CI 0.90-1.20, | ||||||||
Fenten 2018 Netherlands [ | Randomized controlled trial | 153 | 65 | 54% | TKA | LIA of the posterior capsule and a FNB catheter | Periarticular LIA with ropivacaine 0.2% for postoperative analgesia | Proportion of patients using opioids |
I: 7.90%; C: 13.00% No significance test
I: 5.40%; C: 2.60% No significance test |
Hah 2018 USA [ | Randomized controlled trial | 410 | 57 | 58% | Surgeries: orthopeadic (80% of patients), thoracotomy, and breast | Four capsules of gabapentin, 300mg preoperatively and two capsules of gabapentin, 300 mg, 3 times a day postoperatively (10 total doses) | Placebo capsules | Proportion of patients using opioids |
I: 2.40%; C: 2.00% OR 1.22, 95% CI 0.32-4.66, 12 months: I: 1.90%; C: 1.50% OR 1.28, 95% CI 0.28-5.87, |
Thompson 2018 USA [ | Retrospective cohort | 44 | 70 | 68% | TEA | Liposomal bupivacaine mixture through indwelling interscalene catheter | Indwelling interscalene catheter | Cumulative MED |
I: 1,198.60; C: 1,762.50,
|
Sun 2017 USA [ | Retrospective cohort | 120,080 | 57 | 61% | TKA | Nerve Block | No nerve block | Proportion of patients using opioids chronically (having filled 10 or more prescriptions or >120 days’ supply within the first year of surgery, excluding the first 90 postoperative days) |
Opioid naïve: I: 1.78%; C: 1.81%, Adjusted for patient demographics, comorbidities, and preoperative medication use (ARR): 0.98, 98.3% CI 0.847-1.14, Chronic user: I: 67.60%; C: 67.80%,
Intermittent user: I: 6.08%; C: 6.15%, |
Hyer 2015 USA [ | Randomized controlled trial | 70 | 53 | 48% | Spinal surgery | Duloxetine once a day 2 weeks before and more then 3 months after surgery | Placebo capsule | Opioid use |
|
Aguirre 2012 Switzerland [ | Randomized controlled trial | 72 | 58 | 51% | Minimally invasive hip surgery | 20 mL ropivacaine 0.3% applied into the wound as a bolus before wound closure followed with a continuous infusion of ropivacaine 0.3% at 8 mL/h for 48 hours after surgery | NaCl 0.9% placebo | Opioid use |
|
Nader 2012 USA [ | Randomized controlled trial | 62 | 65 | 70% | TKA | Continuous femoral analgesia for 24 hours | Oral opioid analgesia | Median daily MED |
I: 10.00 mg; C: 18.00 mg,
I: 0.00; C: 0.00, |
Chevet 2011 France [ | Prospective cohort | 107 | 72 | 72% | TKA | An intravenous dose of 15 mg/kg of ATX between induction and incision, renewed at the end of surgery | No ATX | Proportion of patients using mild opioids |
I: 20.00%; C: 33.00%, |
Schroer 2011 USA [ | Randomized controlled trial | 107 | 67 | 58% | TKA | Celecoxib 200 mg to twice daily for 6 weeks after discharge | Placebo capsules | Number of opioid pills used (dosage NS) |
I: |
| | |||||||||
Cheesman 2020 USA [ | Randomized controlled trial | 140 | 58 | 32% | ARCR | Formal opioid education (recommended postoperative opioid use, side effects, dependence, and addiction) + a 2-minute computer-based presentation concerning opioid abuse and its consequences + a paper outline on the most important points of the presentation | Standard preoperative education followed by a discussion of risks and benefits. No formal education on opioid use, dependence, and addiction. | Total MED |
Total population: I: 375.00; C:725.00
Opioid-naïve patients: I: 375.00; C: 535.00
Prior opioid use: I: 1,612.00; C:2,475.00
|
| Proportion of opioid dependence (6 opioid prescriptions from the date of surgery) | Total population: I: 11.40%; C: 25.70%
Opioid-naïve patients: I:
Prior opioid use: I: 37.50%; C: 47.60%
| ||||||||
| No of prescriptions filled | Total population: I:
Opioid-naïve patients: I: 1.20; C: 3.40
Prior opioid use: I: 8.90; C: 13.20
| ||||||||
Campbell 2019 USA [ | Randomized controlled trial | 159 | 60 | 45% | THA or TKA | Traditional perioperative education + automated text messages included recovery instructions paired with encouraging and empathetic statements, personalized video messages from their surgeon, and short instructional videos | Traditional perioperative education, which included a preoperative clinic appointment and perioperative instructions | Time to opioids cessation (days) |
I: Mean difference: -10.0, 95% CI -14.2-(-5.7), |
Smith 2018 USA [ | Randomized controlled trial | 561 | 66 | 60% | TKA or THA | Usual care + pharmacist intervention Usual care: an educational session that advised patients on the risks and benefits of surgery, pain control measures and exercise recommendations. Pharmacist intervention: mailed brochures describing what patients should expect regarding opioid use and pain control after and follow-up telephone call from a pharmacist. | Usual Care (handouts and a class in preparation for surgery that advised patients on the risks and benefits of surgery, pain control measures, exercise recommenda-tions, and the need for postsurgical assistance) | Total dispensing of opioid medications |
Adjusted mean difference for patients sociodemographics and probability of long-term opioid use: 0.92 95% CI 0.69-1.21 No readmission for pain control during the study period. |
| | |||||||||
Urban 2021 USA [ | Retrospective cohort | 267 | 67 | 63% | TKA | Preoperative cryoneurolysis (1 min 45 sec cycle in the infrapatellar branches of the saphenous nerve near the knee and branches of the femoral cutaneous nerves in the mid-to-distal anterior thigh + standard multimodal regiment. | Standard multimodal regiment (preoperative protocol + postoperative : oral acetaminophen 500 mg every 6 hours, oral meloxicam 7.5mg twice daily, oral tramadol 50 mg every 6 hours as needed for pain, oral oxycodone 5 mg every 3 hours as needed) | Cumulative MED |
Mean: I: Ratio estimate : |
| Proportion of patients who received | I: 12.00%; C: 20.00% Ratio estimate : 0.61 95% CI 0.29-1.28, | ||||||||
Buys 2020 USA [ | Retrospective cohorte | 336 | 65 | 10 % | RCR, THA, TKA, TSA (veteran population) | Implementation of a Transitional Pain Service. Multidisciplinary providers work together to deliver comprehensive pain management for any surgical patient at risk for CPSP and COU in preoperative, surgical hospitalization and postoperative period up to 6 months. | Before Transitional Pain Service implementation | Proportion of patients still using opioids |
Patients with history of COU I:
Opioid-naïve patients I:
|
Li 2020 USA [ | Prospective cohort | 143 | 66 | 45% | TKA | Multimodal pain management + opioid PRN | Opioid-only analgesia | Cumulative MED |
|
| Proportion of patients who required a refill | I:
| ||||||||
Fleischman 2019 USA [ | Randomized controlled trial | 235 | 63 | 46% | THA |
| No standing dose regimen (acetaminophen 500 mg QID PRN x 4w + Oxycodone q. 4h PRN + tramadol 50 mg q 6 hours PRN) | Cumulative MED |
I1: mean difference: I1: mean difference: |
| Proportion of patients who received opioid refill (%) |
I1: 10.50%; I2: 6.50%; C: 15.60%, No significance test | ||||||||
| Proportion of patients using opioids | I1: 0.00%; I2: 1.30%; C: 2.60%, No significance test | ||||||||
Hannon 2019 USA [ | Randomized controlled trial | 304 | 65 | 54% | THA or TKA | Prescriptions of acetaminophen, meloxicam, gabapentin, tramadol, and | Idem as experimental group and | Cumulative MED |
I: 456.70; C: 455.60,
I: |
| Proportion of patients who received opioid OxyIR refill(s) (%) |
I: 26.70%; C: | ||||||||
Padilla 2019 USA [ | Retrospective cohort | 669 | 65 | 58% | THA | Opioid sparing pain management protocol (intravenous acetaminophen, periarticular injection of liposomal bupivacaine, pre-emptive analgesia in postoperative period) | Before implementation of the opioid sparing protocol | Cumulative MED |
I: |
Tan 2018 Australia [ | Prospective cohort | 230 | 64 | 66% | THA | ERAS program (multimodal analgesia, early mobilization with physiotherapy) | Before ERAS implementation | MED/day |
I: 0.00; C: 0.00, |
| Proportion of patients using opioids (%) | The proportion of patients with zero MED consumption at week 6 increased from | ||||||||
Dasa 2016 USA [ | Retrospective cohort | 100 | 38 | 70% | TKA | Administering perioperative cryoneurolysis and multimodal analgesics regimen | Multimodal analgesics regimen alone. | Cumulative MED |
I:
|
| | |||||||||
Bovonratwet 2021 USA [ | Retrospective cohort | 611 | 63 | 81% | THA | Direct anterior approach | Posterior approach | MED |
|
| Proportion of patients who required a refill |
I: 14.77%; C: 20.73:
I relative to C: relative risk = 0.95, 95% CI 0.55-1.64,
| ||||||||
Varady 2021 USA [ | Retrospective cohort | 92, 506 | 57 | 52% | TJA | Outpatient (no overnight stay) | Inpatient | Proportion of new opioid persistent use (patient still filling opioid prescriptions >90 days postop) |
I: OR, |
Walega 2019 USA [ | Randomized controlled trial | 68 | 66 | 60% | TKA | Genicular nerve radiofrequency aoublation | Sham procedure: simulated GN-RFA using identical supplies and devices | MED/day |
I: 0.00; C: 0.00, |
Verla 2018 USA [ | Retrospective cohort | 46 | 58 | 54% | Spine surgery | Transforaminal lumbar interbody fusions | Direct lateral lumbar interbody fusions | Postoperative opioids duration in months |
I: 5.20; C: 4.80,
I: 4.30; C: 3.14, |
Della Valle 2010 USA [ | Randomized controlled trial | 72 | 63 | 68% | THA | Mini-incision approach | 2 incisions approach | MED/day |
I: 1.30; C: 1.40, |
| | |||||||||
Collinsworth 2019 USA [ | Randomized controlled trial | 40 | 20 | 22% | Shoulder surgery (military population) | Usual care and BFA (semipermanent acupuncture needles emplaced on the subjects’ ears for 3–5 days within 24 hours after shoulder surgery. BFA was reapplied, as needed, up to 6 weeks post-surgically) | Usual postsurgical care (include surgery specific protocols, therapeutic modalities and prescribed/ over-the-counter pain medications | Daily opioid use |
|
| | |||||||||
Hanley 2021 USA [ | Randomized controlled trial | 118 | 65 | 62% | THA, TKA | One 20 minutes session of mindfulness of breath (I1) or mindfulness of pain (I2) 3 weeks preop | One 20 minutes session of cognitive-behavioral pain psychoeducation (C) | Opioid use |
Both MoB and MoP decreased postoperative opioid use relative to C, F(8, 83) = |
Hah 2020 USA [ | Randomized controlled trial | 104 | 66 | 52% | THA, TKA | Motivational interviewing and guided opioid tapering support added to usual care (phone call weekly for postoperative weeks 2-7 and monthly up to 1 year or to opioid cessation) | Usual care + standardized verbal and written instructions on the proper analgesic use of opioids before surgery | Time to base line opioid use return (days) | I: HR |
| Proportion of patients using opioids at 3 months | Overall: I: 2.70%; C:2.00, Opioid naïve: I: 2.70%; C: 9.50%, Preoperative user: I: 8.30%; C: 23.10%, | ||||||||
| Proportion of patients using opioids at 6 months | Overall: I:0.00%; C:5.50%, Opioid naïve: I: 0,00%; C: 2,40%, Preoperative user: I: 0.00%; C: 15.40%, | ||||||||
| Time to postoperative opioid cessation (days) | I: 41.1; C: 76.4 HR 1.57; 95% CI 1.01- 2.44; | ||||||||
| Proportion of opioid cessation | I: 91.80%; C: 87.3%, | ||||||||
Dindo 2018 USA [ | Randomized controlled trial | 75 | 63 | 6% | Orthopedic surgeries (no trauma) | Acceptance and Commitment Therapy (ACT) and treatment as usual | Treatment as usual (a nurse-led patient education class + analgesia with opioids +/- nonopioids, anticonvulsants or anxiolytics regular or as need. Discharge combination of an opioid and acetaminophen | Time to opioid cessation (days) | I: 42.50; C: 51.00; HR 1.44, 95% CI 0.74-2.78 |
| Proportion of patients using opioids |
I: 29.00%; C: 52.00%, OR= 0.39; 95% CI 0.14-1.08 | ||||||||
Abbreviations: ACDF anterior cervical discectomy and fusion, ACLR Anterior cruciate ligament reconstruction, ARCR arthroscopic rotator cuff repair, BFA Battlefield Acupuncture, C Control group, COU Chronic opioid use, CTR carpal tunnel release, ERAS Enhanced recovery after surgery, FAI femoroacetabular impingement, FNB Femoral Nerve Block, HR Hazard ratio, I Intervention group, LIA Local Anaesthetic Infiltration, MED Morphine equivalent dose, OR Odds ratio, ORIF open reduction and internal fixation, RANDOMIZED CONTROLLED TRIAL Randomized control trial, RCR rotator cuff repair, TAA total ankle arthroplasty, THA total hip arthroplasty, TKA Total knee arthroplasty, TSA Total Shoulder Arthroplasty
aConfidence intervals were described when available in the original studies
bTier = Number of pills prescribed according to the type of surgery
Recommendations from guidelines, their level of evidence and their strength
| Author (Sponsor), year, country | Population | Recommendations | Level of evidence |
|---|---|---|---|
|
| |||
| Edwards (ASER, POQI), 2019, USA [ | Patients on preoperative opioids | Patients should be assessed for risk factors for persistent opioid use prior to the initiation of opioid therapy and during therapy to develop and coordinate the pain treatment plan with the health care team. | Recommended (GRADE) |
| Kent (ASER, POQI, 2021, USA [ | Surgery | Suggested | |
| Clarke, 2020, Canada [ | Surgery | Expert consensus | |
| Trexler, 2020, USA [ | TBI | ||
| Soffin, 2017, USA [ | Orthopedic surgery | ||
| Washington State AMDG, 2015, USA [ | All patients | ||
| The committeee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Chou (APS, ASRA, ASA), 2016, USA [ | Surgery | Clinicians should conduct a preoperative evaluation to guide the intraoperative pain management plan. It should include: assessment of medical and psychiatric comorbidities, concomitant medications, history of chronic pain, substance abuse, and previous postoperative treatment regimens and responses. | Strong recommendation, low-quality evidence |
| Soffin, 2017, USA [ | Orthopedic surgery | Opioid tolerance should be diagnosed preoperatively. Referral to an addiction specialist should be made in the presence of opioid-tolerance. | Expert consensus |
| Mai, 2015, USA [ | Musculoskeletal injuries | ||
| Hsu, 2019, USA [ | Trauma | Doses of prescribed controlled substances should be verified via the relevant state Prescription Drug Monitoring Program (PDMP), or by contacting the original prescriber or dispensing pharmacist. | Strong recommendation, low-level of evidence |
| Soffin, 2017, USA [ | Orthopedic surgery | Expert consensus | |
| Mai, 2015, USA [ | Musculoskeletal injuries | ||
| Washington State AMDG, 2015, USA [ | All patients | ||
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Chou (APS, ASRA, ASA), 2016, USA [ | Surgery | Facilities in which surgery is performed should provide clinicians with referral options to a pain specialist for patients with inadequately controlled postoperative pain or at high risk of inadequately controlled postoperative pain (e.g. opioid-tolerant, history of substance abuse) | Strong recommendation, low-quality evidence |
| Clarke, 2020, Canada [ | Surgery | Expert consensus | |
| Sodhi, 2020, USA [ | TJA | ||
| Soffin, 2017, USA [ | Orthopedic surgery | ||
| Mai, 2015, USA [ | Musculoskeletal injuries | ||
| The committee on trauma of the ACS, 2020, USA [ | Trauma | If pain persists beyond 3 months, or if opioid misuse by patient is suspected, the patient should be referred to a transitional/chronic pain clinic or pain management specialist. | No level of evidence |
| The trauma center should provide a pain management service or resources to act as an expert consultant within the trauma service. | |||
| Edwards (ASER, POQI), 2019, USA [ | Patients on preoperative opioids | The patient’s outpatient opioid prescriber should be identified and be contacted to anticipate discharge needs and to coordinate postoperative opioid tapering. | Recommended (GRADE) |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Hsu, 2019, USA [ | Trauma | For patients using illicit opioids, or patients misusing prescription opioids, follow-up should be coordinated with acute pain services (or addiction medicine or psychiatry depending on resources) for inpatients, and with the patient’s prescriber for outpatients, to ensure that there is only 1 prescriber for patients on medication-assisted therapy. | Strong recommendation, moderate-quality evidence |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Hsu, 2019, USA [ | Trauma | Prescribers, to the extent possible, should develop and/or support the implementation of a support system to inform clinical decisions regarding opioid prescription in the electronic medical record. | Strong recommendation, low-level of evidence |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Kent (ASER, POQI), 2021, USA [ | Surgery | Persistent postoperative opioid use occurs when a patient interacts with numerous health care providers and institutions. Addressing system-based characteristics may be more instrumental in tapering persistent opioid use than clinical decision making. Public health initiatives, policies, and legislation at the local, state, and federal levels aimed at safe opioid prescribing should be evaluated with subsequent recommendations for further improvements that target all health care system components. | Strongly recommended |
| Trexler, 2020, USA [ | TBI | Expert consensus | |
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | Complex opioid and non-opioid management should be reimbursed with the time and resources required for patient education; safe evaluation; risk assessment; re-evaluation; and integration of alternative and non-opioid modalities. | Expert consensus |
|
| |||
| Wainwright (ERAS Society), 2020, UK [ | TJA | Add opioids only in the setting of suboptimal analgesia after first-line administration of nonopioid options or when the benefits outweigh the risks | Strongly recommend, High level of evidence |
| Edwards (ASER, POQI), 2019, USA [ | Patients on preoperative opioids | Recommended (GRADE) | |
| Anger (PROSPECT), 2021, USA [ | TJA | Expert consensus | |
| Trexler, 2020, USA [ | TBI, | ||
| Franz (DMGP), 2019 Germany [ | SCI | ||
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | ||
| No level of evidence | |||
| The committee on trauma of the ACS, 2020, USA [ | Trauma | ||
| Hsu, 2019, USA [ | Trauma | The prescriber should use the lowest opioid effective dose for the shortest time period possible. | Strongly recommended, high-quality evidence |
| Edwards (ASER, POQI), 2019, USA [ | Patients on preoperative opioids | Recommended (GRADE) | |
| Trexler, 2020, USA [ | TBI | Expert consensus | |
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | ||
| Soffin, 2017, USA [ | Orthopedic surgery | ||
| Washington State AMDG, 2015, USA [ | All patients | ||
| Edwards (ASER, POQI), 2019, USA [ | Patients on preoperative opioids | The prescriber should avoid opioid dose escalation. | Recommended (GRADE) |
| Washington State AMDG, 2015, USA [ | All patients | Expert consensus | |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | Have a protocol for safe de-escalation of analgesics as quickly as possible. | No level of evidence |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | Promptly investigate the cause of increasing pain rather than responding by increasing the analgesic dose or adding new medications | No level of evidence |
| Hsu, 2019, USA [ | Trauma | Prescribe precisely - Commonly written prescriptions with ranges of dose and duration can allow tripling of daily dose to levels consistent with adverse events. | Strongly recommended, low-level evidence |
| Hsu, 2019, USA [ | Trauma | Avoid long-acting opioids in the acute phase. | Strongly recommended, moderate-quality evidence |
| Trexler, 2020, USA [ | TBI | Expert consensus | |
| Hsu, 2019, USA [ | Trauma | Benzodiazepines should not be prescribed in conjunction with opioids because of the significant risks posed by inconsistent sedation and the potential for misuse. | Strongly recommended, high-quality evidence |
| Trexler, 2020, USA [ | TBI | Expert consensus | |
| Clarke, 2020, Canada [ | Surgery | Patients should receive a prescription based on their opioid consumption in the hospital during the previous 24 hrs that should be written during the discharge process. | Expert consensus |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | Discharge prescriptions should separate opioids and nonopioid analgesics to make opioid tapering easier. | No level of evidence |
| Washington State AMDG, 2015, USA [ | All patients | Strongly consider tapering the patient off opioids as the acute pain episode resolves. | Expert consensus |
| Clarke, 2020, Canada [ | Surgery | The prescription for opioid-containing tablets should have an expiry date of 30 days from the date of discharge | |
| Washington State AMDG, 2015, USA [ | All patients | A part-fill or prescription refill should be given to patients with an expected moderate or long-term recovery to reduce the number of opioid tablets distributed at one time. | Expert consensus |
| Hsu, 2019, USA [ | Trauma | The prescription and continued use of opioids should be based on expected functional recovery, pain, opioid use and adverse events. Complete and regular evaluations are therefore necessary. | Strong recommendation, low-quality evidence |
| Chou (APS, ASRA, ASA), 2016, USA [ | Surgery | ||
| Clarke, 2020, Canada [ | Surgery | Expert consensus | |
| Trexler, 2020, USA [ | TBI | ||
| Mai, 2015, USA [ | Musculoskeletal injuries | ||
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | ||
| Washington State AMDG, 2015, USA [ | |||
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Soffin, 2017, USA [ | Orthopedic surgery | The patient has to be physically present when the initial prescription for a controlled substance is made. No new prescriptions are made or refilled if the patient has not been seen and examined within the prior 30 days. | Expert consensus |
| Clarke, 2020, Canada [ | Surgery | Patients should be discharged with a prescription for the following adjunct pain medications, unless contraindicated: Acetaminophen, NSAIDS | Expert consensus |
| Fillingham (AAHKS, ASRA, AAOS, Hip society, Knee society), 2020, USA [ | TJA | ||
| Sodhi, 2020, USA [ | |||
| Trexler, 2020, USA [ | TBI | ||
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | ||
| Washington State AMDG, 2015, USA [ | |||
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Anger (PROSPECT), 2021, USA [ | TJA | Postoperative NSAID are recommended for their analgesic and opioid-sparing effect. | High-quality evidence |
| Wainwright (ERAS Society), 2020, UK [ | TJA | Strong recommadation, moderate – high level of evidence | |
| Fischer (PROSPECT), 2008, UK [ | TKA | Low level of evidence | |
| Ftouh (NICE), 2011, UK [ | Hip fracture | NSAID should not be used for pain management after a hip fracture because of their poor risk to benefit ratio | Expert consensus |
|
| |||
| Hsu, 2019, USA [ | Trauma | Health service departments should support opioid education efforts for prescribers and patients. | Strongly recommended, moderate-quality evidence |
| Anger (PROSPECT), 2021, USA [ | TJA | Patients should be provided education in the pre-operative period. | High-quality evidence |
| Wainwright (ERAS Society), 2020, UK [ | TJA | Strong recommendation, low level of evidence (GRADE) | |
| Clarke, 2020, Canada [ | Surgery | Patients should receive written and verbal information prior to discharge on the safe storage and disposal of unused opioids. | Expert consensus |
| Trexler, 2020, USA [ | TBI | ||
| Hsu, 2019, USA [ | Surgery | Clinicians should provide education to all patients and / or family and/or primary caregivers: • On treatment options for pain management, the plan and goals for pain management and the pain treatment plan, including analgesic tapering after hospital discharge. • To fill the prescription only if their pain is not adequately managed with other therapies or if they are having difficulty completing activities of daily living secondary to pain. • On the risks and benefits of alternatives to chronic opioid therapy. | Strong recommendation, low-quality evidence |
| Clarke, 2020, Canada [ | Surgery | Expert consensus | |
| Trexler, 2020, USA [ | TBI | ||
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | ||
| Washington State AMDG, 2015, USA [ | |||
| The committee on trauma of the ACS, 2020, USA [ | Trauma | No level of evidence | |
| Chou (APS, ASRA, ASA), 2016, USA [ | Surgery | Patients chronically prescribed opioids before surgery should be instructed: • On how to taper opioids to their target maintenance dose • On who will prescribe controlled substances after surgery and discharge from hospital. | Strong recommendation, low-quality evidence |
| Soffin, 2017, USA [ | Orthopedic surgery | Expert consensus | |
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | Use apps for biopsychosocial treatments to inform physicians, providers, and patients on evidence-based and effective pain management treatments for various chronic pain syndromes more effectively. | Expert consensus |
|
| |||
| Chou (APS3, ASRA4, ASA5), 2016, USA [ | Surgery | Nonopioid therapy should be the first-line of treatment and multimodal analgesia should be used as opposed to opioid monotherapy for pain control. Therapies can be pharmacological or nonpharmacological. | Strong recommendation, high-quality evidence |
| Wainwright (ERAS Society), 2020, UK [ | TJA | ||
| Hsu, 2019, USA [ | Trauma | Strong recommendation, moderate-quality evidence | |
| Edwards (ASER, POQI), 2019, USA [ | Patients on preoperative opioids | Strongly recommended(GRADE) | |
| Galvagno (EAST, TAS), 2016, USA [ | Blunt thoracic trauma | Conditionally recommended, very-low quality evidence | |
| Wu (ASER), 2019, USA [ | Surgery | Expert consensus | |
| Wu (ASER), 2019, USA [ | Surgery | Patients should be discharged home with a comprehensive multimodal analgesia care plan aiming to minimize or avoid post-discharge opioid use. | Expert consensus |
| Chou et al. (APS, ASRA, ASA), 2016, USA [ | Surgery | Health professionals should consider gabapentin or pregabalin as components of multimodal analgesia. | Strong recommendation, moderate-quality evidence |
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | For neuropathic pain, as first-line therapy, consider anticonvulsants (gabapentin, pregabalin, carbamazepine, oxcarbazepine), SNRIs (duloxetine, venlafaxine), TCAs (nortriptyline, amitriptyline), and topical analgesics (lidocaine, capsaicin). | Expert consensus |
| Washington State AMDG, 2015, USA [ | |||
| Chou (APS, ASRA, ASA), 2016, USA [ | Surgery | Health professionals should consider ketamine as a component of multimodal analgesia in adults. | Weak recommendation, moderate-quality evidence |
| Fischer (PROSPECT), 2008, UK [ | TKA | Cooling and compression techniques should be used for postoperative analgesia, based on limited procedure-specific evidence, for a reduction in pain scores and analgesic use. | Low level of evidence |
| Chou et al. (APS, ASRA, ASA), 2016, USA [ | Surgery | Health professionals should consider transcutaneous electrical nerve stimulation (TENS) as an adjunct to other pain management strategies. | Weak recommendation, moderate-quality evidence |
| Washington State AMDG, 2015, USA [ | All patients | In addition to medication, therapies should include physical activation and behavioral health interventions (such as cognitive behavioral therapy, mindfulness, coaching, patient education, and self-management). | Expert consensus |
| Hsu et al., 2019, USA [ | Trauma | Strong recommendation, moderate-quality evidence | |
| U.S. Department of Health ad Human Services (Task Force), 2019, USA [ | All patients | Consider complementary and integrative health approaches, including acupuncture, mindfulness meditation, movement therapy, art therapy, massage therapy, manipulative therapy, spirituality, yoga, and tai chi, in the treatment of acute and chronic pain, when indicated. | Expert consensus |
| The committee on trauma of the ACS, 2020, USA [ | Trauma | Nonpharmacologic pain management strategies are recommended as adjuncts for pain and anxiety management in trauma to minimize opioid use and chronic pain development | No level of evidence |
Abbreviations: ACS American College of Surgeons, AMDG Agency Medical Directors’ Group, APS American Pain Society, ASA American Society of Anesthesiologists, ASER American Society for Enhanced Recovery, ASRA American Society of Regional Anesthesia and Pain Medicine, EAST Eastern Association for the Surgery of Trauma, GRADE Grading of Recommendations Assessment, Development, and Evaluation, NICE National Institute for Health and Clinical Excellence, POQI Perioperative Quality Initiative, TAS Trauma anesthesiology society, Task Force Pain Management Best Practices Inter-agency Task Force, TJA Total joint. Arthroplasty, TKA Total knee arthroplasty
aThis source does not describe any method for classifying the level of evidence of recommendations